The FDA recently approved Imdelltra (tarlatamab-dlle) for extensive-stage SCLC, showing a 44% tumor shrinkage rate in relapsed or treatment-resistant cases.
MediLink Therapeutics presented Phase I clinical data for YL201, a B7H3-targeting antibody-drug conjugate, at ESMO 2024, showcasing its potential in treating advanced solid tumors.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.